Abstract: The KRAS G12D mutation is a highly prevalent oncogenic driver in solid tumors, particularly in colorectal cancer (CRC) and pancreatic ductal adenocarcinoma (PDAC). Historically considered "undruggable" due to the lack of a reactive cysteine residue, KRAS G12D has recently become a viable therapeutic target. Zoldonrasib (RMC-9805) is a breakthrough, first-in-class, orally bioavailable, mutant-selective covalent inhibitor designed to target the active, GTP-bound state of KRAS G12D. By acting as a molecular glue to form a tri-complex with the chaperone protein cyclophilin A, Zoldonrasib enables the covalent modification of the mutant aspartic acid (Asp-12) residue, thereby disrupting downstream oncogenic signaling. Preclinical models demonstrate profound tumor regression and synergy with immunotherapies. Early clinical trials (such as NCT06040541 and NCT06445062) have shown encouraging antitumor activity, deep reductions in circulating tumor DNA (ctDNA), and an acceptable safety profile. Zoldonrasib is currently being investigated both as a monotherapy and in combination with standard-of-care regimens for gastrointestinal malignancies, including CRC, marking a significant advancement in precision oncology.
1. Introduction
The Kirsten rat sarcoma viral oncogene (KRAS) is one of the most frequently mutated oncogenes in human cancers, driving tumorigenesis through continuous, receptor-independent activation of downstream proliferation and survival pathways [1]. The KRAS G12D mutation is particularly prevalent in gastrointestinal malignancies, including colorectal cancer (CRC) and pancreatic ductal adenocarcinoma (PDAC) [3]. Unlike the KRAS G12C mutation, which has been successfully targeted by covalent inhibitors (such as sotorasib and adagrasib) that bind to a reactive cysteine residue in the inactive GDP-bound state, the G12D mutation substitutes glycine with aspartic acid [2][3]. This substitution impairs intrinsic GTPase activity and locks the protein in a persistently active GTP-bound ("ON") state, while lacking a suitable site for traditional covalent binding [3].
To overcome this challenge, Revolution Medicines developed Zoldonrasib (RMC-9805), a novel, oral, selective RAS(ON) G12D inhibitor [3]. Zoldonrasib represents a paradigm shift in targeting KRAS G12D by specifically engaging the active GTP-bound conformation of the mutant protein, offering new therapeutic hope for patients with KRAS G12D-driven solid tumors, including CRC [1][2].
2. Pharmacological Activity
Zoldonrasib has demonstrated robust pharmacological activity in both preclinical and early clinical settings. In preclinical in vitro and in vivo models, RMC-9805 effectively inhibited cell proliferation, suppressed RAS pathway activity, and induced apoptosis [1][2]. In mouse xenograft models of KRAS G12D-mutant tumors, the compound elicited objective responses in 7 out of 9 PDAC models, driving profound tumor regression [2].
Clinically, Zoldonrasib is being evaluated in Phase I/Ib trials (e.g., NCT06040541) for patients with advanced KRAS G12D-mutant solid tumors. Preliminary data presented in 2025 demonstrated highly encouraging antitumor activity, with an objective response rate (ORR) of 61% and a disease control rate (DCR) of 89% in early studies [3]. Furthermore, the drug induced early and deep reductions in KRAS G12D circulating tumor DNA (ctDNA) [1]. For colorectal cancer specifically, Zoldonrasib is being investigated in the NCT06445062 trial, which focuses on gastrointestinal solid tumors. This trial evaluates RMC-9805 in combination with standard-of-care (SOC) therapies for CRC, including 5-fluorouracil-based regimens, cetuximab, and mFOLFOX6 [1].
3. Molecular Mechanism of Action
The molecular mechanism of Zoldonrasib is distinct from first-generation KRAS inhibitors. Because the KRAS G12D mutation lacks a highly reactive cysteine, RMC-9805 utilizes a "tri-complex" mechanism to achieve covalent inhibition [2][3]. Zoldonrasib acts as a molecular glue that first binds to cyclophilin A, an abundant intracellular chaperone protein [3]. The formation of this binary complex induces a conformational change that enables it to bind specifically to the active, GTP-bound ("ON") state of the KRAS G12D protein [2].
Once the tri-complex (Cyclophilin A - RMC-9805 - KRAS G12D) is formed, it facilitates the covalent modification of the mutant Asp-12 residue [3]. By sterically blocking the effector binding interactions, Zoldonrasib effectively disrupts downstream oncogenic RAS signaling pathways, such as the MAPK/ERK and PI3K/AKT cascades, which are critical for tumor cell survival and proliferation [1][3].
4. Structure-Activity Relationship (SAR)
The design of Zoldonrasib overcomes a major structural hurdle in KRAS G12D targeting: the weak nucleophilicity of the aspartic acid carboxylate group compared to the highly reactive thiol group of cysteine found in G12C mutants [3]. Traditional covalent inhibitors rely on strong nucleophilic attack, which is not feasible with Asp-12. The structural innovation of RMC-9805 lies in its ability to leverage cyclophilin A to create a neo-interface. This tri-complex approach precisely positions the electrophilic warhead of the inhibitor in close proximity to the Asp-12 residue, enabling a covalent bond to form despite the residue's poor nucleophilicity [3]. Furthermore, by selectively targeting the GTP-bound conformation, Zoldonrasib ensures high specificity for the active oncogenic driver, minimizing off-target effects on wild-type KRAS [2][3].
5. Current Limitations
While Zoldonrasib shows immense promise, there are current limitations to its clinical application. First, the clinical data available are still preliminary (Phase I/Ib), and long-term efficacy, durability of response, and late-onset toxicities require further investigation [1]. Thus far, the safety profile is acceptable, with no Grade 4 or 5 treatment-related adverse events (TRAEs) reported; the most common Grade 1 or 2 adverse events include nausea, diarrhea, vomiting, and rash [1].
A broader limitation facing all KRAS inhibitors is the inevitable emergence of acquired resistance. Tumor cells can adapt through secondary mutations within the drug-binding pocket, KRAS gene amplification, or the activation of bypass signaling pathways (such as PI3K or alternative receptor tyrosine kinases) that reactivate downstream signaling despite KRAS blockade [2][3]. Additionally, the complex tumor microenvironment in gastrointestinal cancers can foster metabolic adaptations and immunosuppression that may blunt the long-term efficacy of monotherapy [2].
6. Future Perspectives
To maximize the clinical utility of Zoldonrasib in colorectal cancer and other solid tumors, future strategies are heavily focused on combination therapies. Preclinical studies have already demonstrated that combining RMC-9805 with immune checkpoint inhibitors significantly improves antitumor responses by modulating the immunosuppressive tumor microenvironment and promoting cancer-associated neoantigen recognition [2].
Clinically, Zoldonrasib is being integrated into multi-agent regimens to preemptively tackle resistance mechanisms. Ongoing trials (e.g., NCT06445062 and NCT06162221) are evaluating RMC-9805 in combination with pan-RAS inhibitors (like RMC-6236) to provide broader blockade of RAS signaling [1]. For CRC patients, combining Zoldonrasib with established targeted therapies (such as the EGFR inhibitor cetuximab) and chemotherapies (such as mFOLFOX6 or 5-fluorouracil) represents a highly rational approach to achieving deeper and more durable clinical responses [1]. Continued biomarker-driven research will be essential to identify which CRC patient subpopulations will benefit most from these innovative combinations [2].
